This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.
Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line
by Zacks Equity Research
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2017 adjusted earnings per share of 33 cents, a penny ahead of the Zacks Consensus Estimate.
Mead Johnson (MJN) Lags Q1 Earnings, Awaits Merger Closure
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) reported first-quarter 2017 adjusted earnings per share (EPS) of 80 cents at constant exchange rate or CER, down 8% year over year.
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Lowers Guidance
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2017 adjusted earnings per share (EPS) of $2.13, up 6% year over year.
Boston Scientific (BSX) Misses on Q1 Earnings, Updates View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.
Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) moved big last session, as its shares rose almost 10% on the day.
Integra LifeSciences (IART) Misses Q1 Earnings, Retains View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 64 cents in the first quarter of 2017
Edwards Lifesciences (EW) Tops Q1 Earnings, Updates '17 View
by Zacks Equity Research
Edwards Lifesciences Corp. (EW) reported first-quarter 2017 adjusted earnings per share (EPS) of 94 cents, which surpassed the Zacks Consensus Estimate by 14.6%.
NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.
LabCorp (LH) Tops Q1 Earnings, Misses on Sales, Tweaks View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported first-quarter 2017 adjusted earnings per share (EPS) of $2.22, up 8.3% from the year-ago quarter.
Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne
by Zacks Equity Research
Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne
Rockwell Medical (RMTI) Catches Eye: Stock Moves Up 12.1%
by Zacks Equity Research
Rockwell Medical, Inc. (RMTI) moved big last session, as its shares rose over 12% on the day.
Create an Efficient Portfolio with 5 Top Stocks
by Tirthankar Chakraborty
Price performance is believed to be positively correlated with efficiency level.
GNC Holdings (GNC) Q1 Earnings & Revenues Top, Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported first-quarter 2017 adjusted earnings per share (EPS) of 37 cents, reflecting a massive 46.4% year-over-year deterioration.
Boston Scientific's Emerging Markets Grow Amid Currency Woes
by Zacks Equity Research
On Apr 11 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Align (ALGN) Upgraded to Buy on Invisalign System Prospects
by Zacks Equity Research
On Apr 11, leading provider of dental and oral care solutions, Align Technology Inc. (ALGN) was raised to a Zacks Rank #2 (Buy).
Haemonetics' Plasma Group Strong, Blood Center Group a Drag
by Zacks Equity Research
On Apr 11, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE), a leading provider of blood management solutions.
ResMed's Study Results for Central Sleep Apnea Hold Promise
by Zacks Equity Research
ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).
Medtronic HVAD System Results Positive for Long-Term Therapy
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently released results of its ENDURANCE Supplemental trial in regard to HVAD System.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Walgreens Boots (WBA) Meets Q2 Earnings, Retains EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.36 in second-quarter fiscal 2017, up 6.1% year over year.
Walgreens, Prime Form Central Specialty & Mail Service Company
by Zacks Equity Research
Walgreens Boots Alliance (WBA), in a partnership with pharmacy benefit manager (PBM) Prime Therapeutics LLC, recently formed a combined central specialty pharmacy and mail services company AllianceRx .